Clinical Trials Logo

Clinical Trial Summary

The aim of research is to identify markers of acute rejection by VOC analysis in exhaled breath of bilateral-lung transplanted patients. 120 bi-lung transplanted patients will be divided into two groups : patients with acute rejection diagnosed on transbronchial biopsies and patients with no acute rejection. Exhaled breath will be collected for VOC analysis woth electronic nose and mass spectrometry. VOC profiles will be compared between the two groups of patients.


Clinical Trial Description

Prospective single-center study. A single visit, no follow-up. The visit will take place before or within five days from date of transbronchial biopsies (BTB). It will include a noninvasive collection of exhaled breath for VOC analysis. VOC analysis will be conducted using two types of devices: "electronic nose" and mass spectrometry. 200 bi-lung transplanted patients will be enrolled and divided into two groups. - Group A, Acute rejection: 100 patients. Diagnosis of acute rejection retained on transbronchial biopsies or functional anomalies with the necessity of modifying the immunosuppressive regimen. - Group B, control: 100 patients. Patients without respiratory functional abnormality and normal transbronchial biopsy. VOC, detected by electronic nose and identified by mass spectrometry, will be compared between patients with a confirmed diagnosis of acute rejection (group A) and patients without rejection (control group B) The duration of participation of each patient is 1 day. The duration of the inclusion period is estimated at 54 months from the first inclusion. The expected total duration of the research is 54 months ;


Study Design


Related Conditions & MeSH terms

  • Transplant; Complication, Rejection

NCT number NCT03172091
Study type Interventional
Source Hopital Foch
Contact Hélène Salvator, MD
Phone +33(0)046252955
Email h.salvator@hopital-foch.com
Status Recruiting
Phase N/A
Start date June 27, 2017
Completion date October 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04496037 - Mechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney Transplant
Completed NCT01354301 - Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Phase 4
Completed NCT04019353 - Cf-DNA Assay During Treatment of Acute Rejection
Recruiting NCT04855422 - Assessing Benchmarks For Allosure And Allomap Testing in Simultaneous Kidney & Pancreas Transplant Recipients.
Recruiting NCT03422224 - ALLoreactive T-Cell receptOr RePertoire in kidnEy tranSplantation
Active, not recruiting NCT03882164 - Blood-Bile Ratio Tacrolimus After Liver Transplantation
Not yet recruiting NCT05951231 - Liver Transplantation After ex Vivo Liver Perfusion N/A
Recruiting NCT03444675 - The Endoscopic Assesment of Intestinal Grafts
Enrolling by invitation NCT04234139 - Cohort/Ethics Study of Patients With Severe Alcoholic Hepatitis Undergoing Early Liver Transplantation